Ortona L, Pizzigallo E, Federico G
Minerva Med. 1979 Feb 25;70(9):647-54.
The HBeAg-HBeAb system has been studied by means of the microimmunodiffusion technique on agar in patients suffering from acute hepatitis at various stages of the disease, in patients with chronic liver diseases and in asymptomatic carriers of HBsAg. The results correlate the presence of HBeAg with the state of the disease (initial phase of acute or chronic hepatitis) and the presence of HBeAb with clinical cure of an acute hepatitis or with the condition of healthy carrier. It is a personal impression also that an HBsAg + hepatitis can be cured more rapidly the better the immune response expressed by the appearance of HBeAb, and that a lacking or deficient immune response to HBeAg may underlie the chronic course of the disease. Emphasis is also laid on the early disappearance of HBeAb in patients with acute hepatitis, this being matched by its persistence in asymptomatic carriers of HBsAg. In this regard, the first results reported here on the identification of the immune globulin class to which the HBeAb belongs would appear to confirm the hypothesis that the anti-e response is of IgM type in acute hepatitis and of IgG type in HBsAg carriers.
采用琼脂微免疫扩散技术,对处于疾病不同阶段的急性肝炎患者、慢性肝病患者及无症状乙肝表面抗原(HBsAg)携带者的乙肝e抗原(HBeAg)-乙肝e抗体(HBeAb)系统进行了研究。结果表明,HBeAg的存在与疾病状态(急性或慢性肝炎的初始阶段)相关,而HBeAb的存在与急性肝炎的临床治愈或健康携带者状态相关。个人也认为,出现HBeAb所表达的免疫反应越好,HBsAg阳性肝炎就能越快治愈,而对HBeAg缺乏或不足的免疫反应可能是该疾病慢性病程的基础。还强调了急性肝炎患者中HBeAb的早期消失,这与它在无症状HBsAg携带者中的持续存在相匹配。在这方面,此处首次报道的关于鉴定HBeAb所属免疫球蛋白类别的结果,似乎证实了以下假设:急性肝炎中抗e反应为IgM型,而在HBsAg携带者中为IgG型。